A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®

Inclusion Criteria: * Participants must be willing and able to give written informed consent, adhere to trial procedures and able to read and understand English. * Male and female participants 18 to 65 years of age. * Participants must possess a smartphone and is familiar with its use and is willing to download and interact with the Abilify MyCite® app. Participants with a smartphone, that is not compatible with the Abilify MyCite® app will be offered a loaner phone for the trial period. * Clinical diagnosis of schizophrenia and able to ingest oral medication. * Positive and Negative Syndrome Scale (PANSS) total score between 60-90. * Participants currently prescribed oral atypical antipsychotic medication including aripiprazole or appropriate for aripiprazole treatment for 6 months or longer. * Participants are required to have had an inpatient hospitalization for schizophrenia within the last 48 months prior to entering the trial. * Skin on the anterior chest just above the lower edge of the rib cage that is free of any dermatological problems. Exclusion Criteria: * Females who are breast-feeding and/or who are pregnant. * Sexually active males or women of childbearing potential (WOCBP) who do not agree to practice 2 different methods of birth control or remain abstinent during the trial and for 30 days after the last dose of Abilify MyCite®. * Any participants who participated in another clinical trial within 30 days of enrollment. * Participants who are currently being treated with an LAI antipsychotic or have been treated with an LAI in the retrospective 6-month phase. * Participants with a current DSM-5 diagnosis other than schizophrenia. * Participants with a known allergy to adhesive tape or any pertinent components of the patch or aripiprazole tablet embedded with an IEM sensor.